IMMULITE 2000 THYROGLOBULIN

Additional Manufacturer Narrative

A US CUSTOMER CONTACTED THE SIEMENS CUSTOMER CARE CENTER (CCC) TO REPORT IMPRECISION INVOLVING QUALITY CONTROL SAMPLES AND ISSUES WITH ADJUSTMENT ON THE IMMULITE 2000 SYSTEMS WHEN USING THYROGLOBULIN KIT LOT D433. THE ISSUE WAS OBSERVED ON ALL 4 IMMULITE SYSTEMS IN THE CUSTOMER'S LABORATORY. SIEMENS HEALTHCARE DIAGNOSTICS FURTHER INVESTIGATED THE ISSUE AND HAS CONFIRMED THE POTENTIAL FOR FUNCTIONAL SENSITIVITY TO NOT MEET INSTRUCTIONS FOR USE CLAIMS WITH THYROGLOBULIN KIT LOTS D431-D436 (US) AND KIT LOTS 431-436 (OUTSIDE THE US). INVESTIGATION HAS ALSO DEMONSTRATED THAT IMMULITE THYROGLOBULIN CONTROL MODULE CONTROL LEVEL ONE MAY RESULT OUTSIDE OF PUBLISHED RANGES. PER GOOD LABORATORY PRACTICE, PATIENT RESULTS ARE NOT REPORTED WHEN CONTROLS RESULT OUT OF RANGE. WHEN CONTROL RESULTS ARE IN RANGE, USERS MAY OBSERVE INCREASED IMPRECISION WITH LOW LEVEL PATIENT SAMPLES. AN URGENT MEDICAL DEVICE CORRECTION (UMDC, LETTER IMC23-04.A.US) WAS SENT TO US CUSTOMERS (B)(6) 2022 , AND AN URGENT FIELD SAFETY NOTICE (UFSN, LETTER IMC23-04.A.OUS) WAS SENT TO OUTSIDE THE US (OUS) CUSTOMERS ON (B)(6) 2022 . THE UMDC AND UFSN EXPLAIN THE POTENTIAL FOR FUNCTIONAL SENSITIVITY NOT MEETING IFU CLAIMS AND INCREASED IMPRECISION WITH PATIENT SAMPLES WITH LOW LEVEL PATIENT SAMPLES.

Description of Event or Problem

THE CUSTOMER INDICATED IMPRECISION INVOLVING QUALITY CONTROL SAMPLES AND ISSUES WITH ADJUSTMENT ON THE IMMULITE 2000 SYSTEMS WHEN USING THYROGLOBULIN KIT LOT D433. THE ISSUE WAS OBSERVED ON ALL 4 IMMULITE SYSTEMS IN THE CUSTOMER'S LABORATORY. THERE WERE NO PATIENT RESULTS GENERATED OR REPORTED. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE FAILED QUALITY CONTROL SAMPLES.